WO2002017923A1 - Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors - Google Patents

Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors Download PDF

Info

Publication number
WO2002017923A1
WO2002017923A1 PCT/IB2001/001557 IB0101557W WO0217923A1 WO 2002017923 A1 WO2002017923 A1 WO 2002017923A1 IB 0101557 W IB0101557 W IB 0101557W WO 0217923 A1 WO0217923 A1 WO 0217923A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mixtures
group
glycol
sorbitan
Prior art date
Application number
PCT/IB2001/001557
Other languages
English (en)
French (fr)
Inventor
Vinod Kumar Arora
Ajay Kumar Singla
Mukesh Kumar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to CA002420804A priority Critical patent/CA2420804A1/en
Priority to JP2002522896A priority patent/JP2004525859A/ja
Priority to EP01963295A priority patent/EP1315500A4/en
Priority to AU2001284321A priority patent/AU2001284321A1/en
Priority to US10/363,326 priority patent/US20040029946A1/en
Priority to SK362-2003A priority patent/SK3622003A3/sk
Priority to BR0113661-5A priority patent/BR0113661A/pt
Publication of WO2002017923A1 publication Critical patent/WO2002017923A1/en
Priority to PCT/IB2002/004401 priority patent/WO2003035080A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition for
  • topical delivery comprising a pharmaceutically effective amount of drug(s) that
  • the bioavailability desired is systemic, dermal, regional or localized. This
  • hepatic first-pass metabolism avoids the variable systemic absorption and metabolism and also, potentially reduces gastro-intestinal irritation associated
  • U.S. Patent No. 5,093,133 discloses a hydroalcoholic gel of pH 3.5-6.0 consisting essentially about 1-15% substantially pure S-ibuprofen, 0-20% of propylene glycol, about 40-60% alcohol, about 2-5% of a gelling agent selected from the group consisting of hydroxypropyl cellulose and polyacrylic acid polymers and about 0.25-2% of triethanolamine to adjust the pH.
  • a gelling agent selected from the group consisting of hydroxypropyl cellulose and polyacrylic acid polymers and about 0.25-2% of triethanolamine to adjust the pH.
  • the rate of delivery of ibuprofen from such a system is allegedly pH dependent. It is believed that such a topical system wherein such high concentration of alcohol is used, repeated application could cause unfavourable conditions.
  • U.S. Patent No. 5,976,566 describes the use of 1 ,3-dioxane and 1 ,3- dioxolane derivatives or acetal as skin penetration enhancers for NSAIDs. It discloses a substantially neutral ibuprofen containing alcoholic or aqueous alcoholic composition which comprises a skin penetration enhancing effective amount in the range of from about 4-15% of a C to C ⁇ - hydrocarbyl substituted 1 ,3 dioxolane, 1 ,3-dioxane or acetal, about 0-18% of glycol, at least about 40% of volatile alcohol, base to provide a pH in the range of from about 6.5 to about 8 and, optionally, gelling agent effective to thicken the composition to avoid or minimize run-off when applied to the skin.
  • the penetration enhancers used therein are unstable at lower pH.
  • the invention is particularly adapted only for NSAIDs in substantially neutral salt form (pH 6- 8) which allegedly makes the gel formulation stable.
  • U.S. Patent No. 4,602,040 describes non-aqueous clear gel and topical cream composition of meclofenamic acid.
  • the patent discloses a clear gel formulation of meclofenamic acid in a cosolvent system of a polyethylene glycol ester, water soluble lanolin oil, an alcohol and a thickening agent and a cream formulation which is homogenized emulsion of polyethylene glycol ester, glyceryl or propylene glycol ester, triglyceride and mineral oil.
  • An anti-inflammatory analgesic gel composition as disclosed through
  • U.S. Patent No. 4,393,076 comprises ketoprofen as the active ingredient, a glycol, lower alcohol, water and/or a mixture of a lower alcohol with water, a gel forming agent and optionally, a solubilizing agent and/or nonionic surface active agents as penetration enhancers.
  • U.S. Patent No. 5,807,568 describes enhanced delivery of flurbiprofen through topical compositions comprising 0.5 to 10% of active, about 10-80% of a lower alcohol, about 0-25% of a glycol, about 0-5% of a gelling agent, an amount of a pH adjusting agent sufficient to adjust the pH of the composition to a range of from about 2 to less than 4.5 and water in an amount sufficient to make up the composition.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • Adverse reactions mostly associated with gastrointestinal disturbances such as acidity, ulceration, hepatic and nephric disorders etc. have been reported with repeated oral NSAID therapy. Hitherto, topical application is one of the preferred alternative routes of administration. Direct application to inflammed joints results in appreciably lower systemic blood levels, reduced gastrolesivity and thereby better tolerance.
  • NSAIDs are known to act through inhibition of cyclooxygenase and lipoxygenase pathway of arachidonic acid metabolism.
  • the cyclooxygenase (COX) enzyme catalyses the first step in the conversion of arachidonic acid to prostanoids (prostaglandins and thromboxanes).
  • the central mechanism leading to the therapeutic effects of NSAIDs is through the blockade of prostagladin synthesis resulting from inhibition of cyclooxygenase enzyme.
  • the gastrointestinal adverse effects of these drugs are also largely attributable to cyclooxygenase inhibition.
  • Recent research has revealed that this enzyme exists in 2-isoforms, COX-1 and COX-2. It is proposed that inhibition of COX-1 results in their shared adverse effects, whilst COX-2 being the primary isoform available at the sites of inflammation, its inhibition accounts for the therapeutic benefits of NSAIDs.
  • the principal object of the present invention is to provide a process for the preparation of pharmaceutical compositions for topical delivery of COX-2 enzyme inhibitors. It is a further object of the present invention to provide a process for the preparation of such compositions which provide enhanced skin penetration and achieve therapeutic levels of the COX-2 enzyme inhibitors in target internal tissues.
  • Yet another object of the present invention is to provide a process for the preparation of such compositions that have good stability and good cosmetic characteristics.
  • An additional object of the present invention is to provide a vehicle which is suitable for topical application to the skin and that results in rapid penetration of COX-2 enzyme inhibitor dissolved or suspended therein.
  • the present invention relates to a pharmaceutical composition containing as drug a cyclooxygenase-2 enzyme inhibitor for topical application, which effects readier solubility of the active ingredient and which transports the active through the barrier of the stratum corneum, and to the use thereof.
  • the present invention describes a process for the preparation of a pharmaceutical composition for topical delivery comprising a pharmaceutically effective amount of drug(s) that acts selectively as a cyclooxygenase-2 enzyme inhibitor, from about 0.3% to about 40% of a gelling agent, from about 2% to about 60% of a solubilizing agent, and optionally, a pH modifying agent and/or other pharmaceutically acceptable adjuvants, said percentages being w/w of the composition.
  • the present invention also comprehends a pharmaceutical composition incorporating COX-2 inhibitor in the carrier base and optional pharmaceutical adjuvants such as penetration enhancers, humectants and/or moisturizers, preservatives, opacifiers, fragrances, color additives, counter-irritants, and the like.
  • pharmaceutical adjuvants such as penetration enhancers, humectants and/or moisturizers, preservatives, opacifiers, fragrances, color additives, counter-irritants, and the like.
  • compositions of the invention are intended for topical, non-invasive application to the skin, particularly to the region where the COX-2 enzyme inhibitor is intended to exert its pharmacological activity, usually to a region of inflammation, injury or pain, to the muscles or joints, or other forms of cutaneous disorders or distruptions characterized by skin inflammation and/or hyperproliferative activity in the epidermis of skin.
  • the pharmaceutical compositions is such that it provides release of at least one therapeutic agent or drug.
  • the drug may be pharmacologically active itself or may be converted into the active form by biotransformation in the body.
  • the combination of drugs that are typically administered together may be included as the drug component. However, in embodiments wherein such a combination is used at least one of such drug acts selectively as a cyclooxygenase-2 enzyme inhibitor.
  • the composition contains celecoxib or rofecoxib as the drug.
  • the drug itself or its pharmacologically active salt or ester can be used in the present invention.
  • the amount of drug suitable for the present invention is that which is typically administered for a given period of time. This includes a pharmaceutically effective amount of the drug which is an amount high enough to significantly positively modify the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit / risk ratio), within the scope of sound medical judgement.
  • the precise amount of drug will vary with the specific drug, the ability of the composition to penetrate the drug through the skin, the amount of the composition to be applied, the particular condition being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the age and physical condition of the patient being treated, and the like factors. Accordingly, the drug dissolved or dispersed therein, may be present in amount ranging from a pharmaceutically effective amount upto 25% by weight of the total weight of the composition.
  • the composition contains an agent which provides the desired integral gel structure to the composition.
  • gelling agents to be used are considered to be within the purview of one skilled in the art, provided they are compatible with the drug, solubilizing agents and other adjuvants.
  • the gelling agents preferred for the present invention include inorganic and organic macromolecules capable of forming gel structure. They may be of the hydrophilic or the hydrophobic type or pH dependent or pH independent in nature.
  • Examples of gelling agents suitable for this invention include the agents well known in the pharmaceutical art for their gelling properties and may be selected from the group comprising cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxyethyl methylcellulose, methylcellulose, hydroxypropyl ethylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxycellulose, and the like; vinyl alcohols such as Polyviol or Moviol, and the like; vinyl pyrrolidones such as Kollidon or Plasdone, and the like; natural gums such as karaya gum, locust bean gum, guar gum, gelan gum, xanthan gum, gum arabic, tragacanth, carrageenan, pectin, a
  • the composition contains polyacrylate or poloxamer as the gelling agent.
  • the requisite amount of gelling agent used in this invention is an amount needed to obtain a gel formulation of desirable consistency that allows for easy application to the skin.
  • a low concentration of gelling agent makes the formulation loose or fluid which runs on application, while higher concentration results in stiff formulation that are not easily spreadable.
  • the gelling agents may be present from about 0.3% to about 40% or preferably from about 0.5% to about 30% by weight of the total weight of the composition.
  • the pharmaceutical composition contains solubilizing agents which aids in the solubility and better penetration of the drug through skin.
  • the solubilizing agents may be volatile, or non- volatile in nature or a combination thereof.
  • compositions of the invention may contain a volatile solubilizing agent that includes especially lower alkanols having preferably 2 or 4 carbon atoms such as ethanol, denatured ethanol (commercially available as SDA-
  • the compositions may comprise non-volatile solubilizing agent.
  • non-volatile solubilizing agents that may be used in the present invention include glycols and derivatives thereof such as butylene glycol, propylene glycol, polypropylene glycol, polyethylene gycol, hexylene glycol, polyethylene glycol dodecyl ether, diethylene glycol monoethyl ether (available commercially as Transcutol), polyethylene glycol-8 glyceryl caprylate (commercially available as Labrasol), propylene glycol monocaprylate (commercially available as Capryol 90), and the like; polysorbates such as available as Tween 20, Tween 40, Tween 60, Tween 80, and the like; Sorbitan esters such as sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan trioleate (Span 85), and the like; poly
  • the total amount of the solubilizing agent used depends on the factors such as amount of COX-2 inhibitor, type of COX-2 inhibitor, amount and nature of gelling agent, and the like.
  • the composition of the invention may contain solubilizing agents in an amount from about 2% to about 60%, preferably from about 5% to about 50% and more preferably from about 10% to about 40% by weight of the total weight of the composition.
  • the pharmaceutical composition contains combination of ethanol, polyethylene glycol-8 glyceryl caprylate, polyethylene glycol and propylene glycol as the solubilizing agents.
  • compositions containing alcohol are of great utility in solubilizing active ingredients which are poorly soluble in glycol but highly soluble in alcohol.
  • the alcohol contained in the composition exerts a bactericidal and bacteriostatic effects on skin areas to which the compositions are applied, and provides a cooling counter-balance to the glycol solubilizing agents which may sometimes create a warming sensation when applied to the skin.
  • the solubilizing agents disclosed herewith provide unique advantages. Such a system provide stable non-irritating composition of a wide variety of drugs and aids in penetration of COX-2 enzyme inhibitors with even high molecular weights through the skin.
  • alcohol and glycols as a solubilizing agent improves solubility of polar drugs and those that are primarily sparingly soluble in water.
  • a combination promotes improved resorbability of the COX-2 enzyme inhibitor.
  • a combination improves spreadability and aestethics of the pharmaceutical composition. It minimizes any congealing or balling up or drying of the composition when it is rubbed on the skin.
  • polyethylene glycol-8 glyceryl caprylate being a surfactant acts as a permeation enhancer and hence improves penetration of the COX-2 enzyme inhibitor.
  • the compositions may also comprise a pH modifying agent.
  • the present invention is directed to a pharmaceutical composition exhibiting an optimal flux or diffusion for the topical delivery of COX-2 enzyme inhibitors. It is well known to the one skilled in art that composition at optimal pH maximizes the flux i.e. the rate of delivery of the drug through skin.
  • most gelling agents usable in accordance with the present invention are highly acidic which drop the pH below the desirable range.
  • certain gelling agents in accordance with the present invention forms integral gel structure only at near neutral pH.
  • Carboxyvinyl polymers is one such example. These are hydrophillic polymers that are prepared by polymerizing monomers principally consisting of acrylic acid. Due to the presence of free carboxylic acid residues, an aqueous solution of this polymer is acidic in nature. Neutralization of this solution cross-links and gelatinizes the polymer to form a viscous integral structure of desired viscosity.
  • any well known and pharmacologically safe inorganic or organic basic compounds can be used for modifying the pH.
  • inorganic basic salts that may be used in the present invention include ammonium hydroxide, alkali metal salts, alkaline earth metal salts such as magnesium oxide, magnesium hydroxide, calcium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, aluminium hydroxide, potassium carbonate, sodium bicarbonate, and the like.
  • the pharmaceutical composition contains triethanolamine as the pH modifying agent.
  • the drug and likewise the other ingredients may be selected to achieve the desired release profile and the extent of penetration.
  • the optimum pH may then be determined and will depend on factors such as nature of COX-2 enzyme inhibitor, gelling agent, degree of flux required, and the like.
  • the pH of the pharmaceutical composition according to the present invention may be between 3.0 and 8.0, and preferably between 4.0 and 7.0.
  • composition of the present invention may also be incorporated into the pharmaceutical composition of the present invention other conventional pharmaceutically acceptable adjuvants known in the art of formulation development such as penetration enhancers, humectants and/or moisturizers, preservatives, opacifiers, fragances, color additives, counter-irritants and the like.
  • adjuvants selected should be such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition of the present invention.
  • Pharmaceutical adjuvants used must be of high purity and low toxicity to render them suitable for administration.
  • the composition of the invention may further comprise penetration enhancers for improved transepidermal or percutaneous delivery of drug.
  • the penetration enhancers suitable for the present invention include terpenes, terpene alcohols, essential oils, surfactants, and the like. Some such examples include d-limonene, terpinen-4-ol, menthone, 1 ,8-cineole, 1-pinene, ⁇ -terpineol, carveol, carvone, pulegone, eucalyptol, peppermint oil, sorbitan
  • esters polysorbates, sodium lauryl sulphate, and the like.
  • compositions in accordance with the present invention may also contain one or more humectants and/or moisturizers.
  • humectants and/or moisturizers may include polyhydroxy alcohols such as sorbitol, glycerin, hexanetriol, butanediol, mannitol, glucose, ethylene glycol, propylene glycol, and the like.
  • Preservatives such as methylparaben, propylparaben, phenoxyethanol, benzyl alcohol, bromopol, chlorocresol, thiomersal, benzalkonium chloride, and the like may be added to the compositions to inhibit microbial activity.
  • Opacifiers such as behenic acid, glycol distearate, lard glycerides, polyethylene glycol esters, and the like; fragrances such as amyl salicylate, p- anisaldehyde, anisylalcohol, peppermint oil, wintergreen oil, and the like; colour additives such as quinoline yellow, and the like; counter-irritants such as methyl salicylate, menthol and the like; and other pharmaceutical adjuvants may be added to the compositions of the invention.
  • fragrances such as amyl salicylate, p- anisaldehyde, anisylalcohol, peppermint oil, wintergreen oil, and the like
  • colour additives such as quinoline yellow, and the like
  • counter-irritants such as methyl salicylate, menthol and the like
  • other pharmaceutical adjuvants may be added to the compositions of the invention.
  • the composition of the present invention may have a viscosity of within the range of about 50,000 to 3.5 million centipoises (cps), preferably between about 300,000 to 2.5 million cps, and even more preferably between about 800,000 to 2.0 million cps, when measured using a
  • Brookfield type RVT series viscometer with helipath stand at ambient temperature (20°C) and with a 0.5 inch helipath and T-spindle (size "E") rotating at 2.5 RPM in a sample size ranging from 90-100 grams.
  • the compositions hereof have good stability. They do not show any substantial changes in viscosity at high temperatures or crystallization at low temperatures. Moreover, they adhere well to the skin and spread readily. Further, they do not impart a sticky feeling and dry easily.
  • the in vitro release profiles were characterized using modified Franz diffusion cells consisting of two compartments, a donor and a receptor,
  • test product was uniformly spread, whilst isopropyl alcohol and water mixture was used as a medium to maintain the sink conditions in the receptor compartment.
  • the cellulose acetate nitrate membrane hinders the penetrant as it diffuses through its channels and the transport process correlates at best with molecular permeation across porous capillary endothelium.
  • the transport mechanism is diffusion or passage through macroscopic ducts filled with solvent. All studies were conducted at 32°C.
  • This example illustrates the preparation of pharmaceutical composition using carboxyvinyl polymer as the gelling agent in conjuction with the solubilizing agent comprising glycols, alcohol and surfactant.
  • the active ingredient is celecoxib.
  • the pharmaceutical composition is given below in Table 1.
  • This example illustrates the preparation of pharmaceutical composition using carboxyvinyl polymer as the gelling agent in combination with glycols, alcohols and surfactant as solubilizing agents.
  • the active ingredient is Rofecoxib.
  • the pharmaceutical composition is given below in Table 3.
  • Polyethylene glycol, propylene glycol, polyethylene glycol-8 glyceryl caprylate and phenoxyethanol were stirred well to form a dispersion.
  • Rofecoxib was then added slowly under continuous stirring. The stirring was continued till a uniform dispersion was formed.
  • Carboxyvinyl polymer was further dispered in the resultant dispersion following which a portion of water was added. Ethanol, fragrance and a solution of triethanolamine was then dispersed. The weight was made upto 500g with purified water and the resultant mixture was thoroughly agitated until a homogenous composition was obtained.
  • the resultant composition had a pH of 5.87 and a viscosity of 1 ,50,000 cps.
  • composition was studied for in vitro release profile using modified Franz diffusion cell and the samples of the receptor media (IPA: Water:: 70:30) were analyzed for rofecoxib content at prescheduled timings, spectro- photometrically. The results are tabulated in Table 4.
  • This example illustrates the preparation of pharmaceutical composition using carboxyvinyl polymer as the gelling agent in combination with a solubilizing agents containing only glycols and alcohol.
  • the pharmaceutical composition is given below in Table 5.
  • the pharmaceutical composition was prepared as described in
  • Example 2 The composition with a pH of 5.82 and a viscosity of 1 ,40,000 cps was obtained. The composition was studied for in vitro release profile as described in Example 2. The results are tabulated in Table 6.
  • This example illustrates the use of polyoxyethylene-polyoxypropylene copolymer as the gelling agent.
  • the pharmaceutical composition is given in Table 7.
  • Polyethylene glycol, propylene glycol, polyethylene glycol-8 glyceryl caprylate, ethanol and phenoxyethanol were stirred to form a clear dispersion.
  • Celecoxib was then added slowly under continuous stirring. The stirring was continued till a clear solution was obtained.
  • Polyoxyethylene-polyoxypropyl- ene copolymer (Lutrol) was heated to 60-70°C. This was cooled to 50°C and the drug solution prepared above, was added to lutrol base under continuous stirring. Fragrance was then dispersed and purified water was added. The resultant mixture was stirred well till a homogenous clear composition of 500g was obtained.
  • the resultant composition had a pH of 5.97 and a viscosity of
  • composition was studied for in vitro release characteristics as described in Example 1. The results are shown in Table 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/IB2001/001557 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors WO2002017923A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002420804A CA2420804A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
JP2002522896A JP2004525859A (ja) 2000-08-29 2001-08-28 シクロオキシゲナーゼ−２酵素阻害剤の局所配送用医薬組成物
EP01963295A EP1315500A4 (en) 2000-08-29 2001-08-28 PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION OF CYCLOOXYGENASE-2 INHIBITORS
AU2001284321A AU2001284321A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US10/363,326 US20040029946A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
SK362-2003A SK3622003A3 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
BR0113661-5A BR0113661A (pt) 2000-08-29 2001-08-28 Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
PCT/IB2002/004401 WO2003035080A2 (en) 2001-08-28 2002-10-23 A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN779/DEL/2000 2000-08-29
IN779DE2000 IN191090B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-08-29 2000-08-29

Publications (1)

Publication Number Publication Date
WO2002017923A1 true WO2002017923A1 (en) 2002-03-07

Family

ID=11097085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001557 WO2002017923A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Country Status (13)

Country Link
US (1) US20040029946A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1315500A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2004525859A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1227012C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2001284321A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0113661A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2420804A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2003822A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191090B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2003108335A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK3622003A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002017923A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200301680B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096435A3 (en) * 2001-05-31 2003-05-01 Pharmacia Corp Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
WO2004000275A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal aerosol compositions
WO2004000263A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
WO2004012734A1 (ja) * 2002-08-02 2004-02-12 Hisamitsu Pharmaceutical Co., Inc. 経皮投与用貼付剤
JP2007522077A (ja) * 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
US20070196301A1 (en) * 2005-12-21 2007-08-23 L'oreal Cosmetic composition with a volumizing effect
AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
EP1515744A4 (en) * 2002-05-31 2008-04-16 Aradigm Corp COMPOSITIONS, METHODS AND SYSTEMS FOR THE PULMONARY ADMINISTRATION OF RECOMBINANT HUMAN INTERFERONE ALPHA-2B
US20110178044A1 (en) * 2003-10-14 2011-07-21 Tsung-Min Hsu Transdermal administration of hydrophilic drugs using permeation enhancer composition
US8071075B2 (en) 1996-02-19 2011-12-06 Acrux Dds Pty Ltd. Dermal penetration enhancers and drug delivery systems involving the same
EP1800649B2 (fr) † 2005-12-21 2012-10-10 L'Oréal Composition cosmétique à effet volumateur
US12226423B2 (en) 2016-08-02 2025-02-18 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
KR101816958B1 (ko) 2010-12-28 2018-01-09 마리 케이 인코포레이티드 피지 조절 및 항여드름 조성물
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP6495723B2 (ja) * 2015-04-14 2019-04-03 帝國製薬株式会社 セレコキシブの経皮吸収製剤
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
CN107158407A (zh) * 2017-06-17 2017-09-15 安徽仁之堂药业有限公司 一种中药提取所得挥发油的制剂助剂
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
AU2021205506A1 (en) * 2020-01-10 2022-08-04 Jf Pharma Tech Llc Topical compositions containing rofecoxib and methods of making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046191A (en) * 1997-10-10 2000-04-04 Astra Pharmaceuticals Ltd. Combination
WO2000032189A1 (en) * 1998-11-30 2000-06-08 G. D. Searle & Co. Celecoxib compositions
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075837B (en) * 1980-05-14 1984-03-14 Hisamitsu Pharmaceutical Co Topical pharmaceutical gel containing anti-inflammatory analgesic agents
US4602040A (en) * 1983-04-18 1986-07-22 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
PL185510B1 (pl) * 1995-02-13 2003-05-30 Searle & Co Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
AU5460800A (en) * 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
IN191512B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2000-01-21 2003-12-06 Panacea Biotech

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6046191A (en) * 1997-10-10 2000-04-04 Astra Pharmaceuticals Ltd. Combination
WO2000032189A1 (en) * 1998-11-30 2000-06-08 G. D. Searle & Co. Celecoxib compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1315500A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071075B2 (en) 1996-02-19 2011-12-06 Acrux Dds Pty Ltd. Dermal penetration enhancers and drug delivery systems involving the same
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
WO2002096435A3 (en) * 2001-05-31 2003-05-01 Pharmacia Corp Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
EP1515744A4 (en) * 2002-05-31 2008-04-16 Aradigm Corp COMPOSITIONS, METHODS AND SYSTEMS FOR THE PULMONARY ADMINISTRATION OF RECOMBINANT HUMAN INTERFERONE ALPHA-2B
WO2004000275A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal aerosol compositions
WO2004000263A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8784878B2 (en) 2002-06-25 2014-07-22 Acrux DDS Pty Ltc. Transdermal delivery rate control using amorphous pharmaceutical compositions
EA007351B1 (ru) * 2002-06-25 2006-10-27 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
US8357393B2 (en) 2002-06-25 2013-01-22 Acrux Dds Pty Ltd. Transdermal delivery rate control using amorphous pharmaceutical compositions
EA009024B1 (ru) * 2002-06-25 2007-10-26 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Фармацевтическая композиция для чрескожной доставки активного агента (варианты)
AU2003240301B2 (en) * 2002-06-25 2008-02-14 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
JP2004067539A (ja) * 2002-08-02 2004-03-04 Hisamitsu Pharmaceut Co Inc 経皮投与用貼付剤
WO2004012734A1 (ja) * 2002-08-02 2004-02-12 Hisamitsu Pharmaceutical Co., Inc. 経皮投与用貼付剤
JP2007522077A (ja) * 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
US20110178044A1 (en) * 2003-10-14 2011-07-21 Tsung-Min Hsu Transdermal administration of hydrophilic drugs using permeation enhancer composition
US20070196301A1 (en) * 2005-12-21 2007-08-23 L'oreal Cosmetic composition with a volumizing effect
EP1800649B2 (fr) † 2005-12-21 2012-10-10 L'Oréal Composition cosmétique à effet volumateur
US10220223B2 (en) 2005-12-21 2019-03-05 L'oreal Cosmetic composition with a volumizing effect
US12226423B2 (en) 2016-08-02 2025-02-18 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Also Published As

Publication number Publication date
CA2420804A1 (en) 2002-03-07
JP2004525859A (ja) 2004-08-26
IN191090B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-09-20
ZA200301680B (en) 2004-06-23
CN1227012C (zh) 2005-11-16
RU2003108335A (ru) 2004-09-10
CZ2003822A3 (cs) 2003-08-13
CN1469748A (zh) 2004-01-21
EP1315500A4 (en) 2006-05-31
AU2001284321A1 (en) 2002-03-13
SK3622003A3 (en) 2003-09-11
EP1315500A1 (en) 2003-06-04
BR0113661A (pt) 2004-07-06
US20040029946A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
US20040029946A1 (en) Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US5807568A (en) Enhanced delivery of topical compositions containing flurbiprofen
US9675562B2 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20140314815A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
AU2005221427B2 (en) Novel compositions for topical delivery
US20060211688A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
JPH04210914A (ja) 水アルコール性ゲルを用いるイブプロフエンの経皮デリバリー方法
US20120157536A1 (en) Composition for transdermal administration of non-steroidal anti-flammatory drug
US20150297507A1 (en) Diclofenac formulations
US20050049291A1 (en) Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
JP2007536312A (ja) 抗コリン作用薬のための透過性増強組成物
US20240382502A1 (en) Compositions and methods for deep dermal drug delivery
JP4195178B2 (ja) 消炎鎮痛外用剤
JP2023525160A (ja) 毛包内への生物活性剤の送達のための組成物
WO2006103638A2 (en) Topical pharmaceutical compositions of terbinafine and processes for their preparation
JP2001064206A (ja) 経皮吸収促進組成物
KR101894891B1 (ko) 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형
TWI308873B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
US11376213B2 (en) Topical pharmaceutical formulation
CA2500907A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
WO2020086038A2 (en) Topical compositions comprising tolperisone and selective cox-2 inhibitor combination
KR20020061281A (ko) 속효성이고 흡수성이 높은 외용제 조성물
KR20000066357A (ko) 케토롤락 외용제제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001963295

Country of ref document: EP

Ref document number: 2420804

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/01680

Country of ref document: ZA

Ref document number: 200301680

Country of ref document: ZA

Ref document number: 2002522896

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001284321

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2003-822

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 3622003

Country of ref document: SK

Ref document number: 524899

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003108335

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018172873

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001963295

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10363326

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-822

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2003-822

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001963295

Country of ref document: EP